Regulatory Reforms Reshape Opioid Treatment
As the opioid crisis continues, regulatory updates under CFR 42 have been drafted to reshape Opioid Treatment Programs (OTPs). These changes (initially explored in our previous article) are designed to meet the evolving needs of patients and providers by promoting practitioner autonomy, modernizing treatment, and incorporating technological solutions. In this article, we’ll explore how we can responsibly exercise the new regulations to enhance care without compromising safety and trust.
Change Is Urgent and Welcomed
The urgency for the recent round of updates is underscored by staggering statistics on opioid use disorder (OUD) and overdose deaths. Current estimates indicate that over 16 million people worldwide are grappling with OUD.1 Between 2 and 7.6 million of these people are in the US alone.1, 2 The death toll of the epidemic is stark, with more than 80,000 fatal opioid overdoses in the US in 2021—a tenfold increase since 1999.3 Synthetic opioids such as fentanyl are implicated in nearly 88% of those deaths.3
Despite the alarming prevalence of OUD, the majority of those affected are less likely to seek help, exacerbating the treatment gap. In 2020, only 11% of individuals with OUD received Medication Assisted Treatment (MAT), and among those who did receive treatment, retention rates were notably low.4-6 This confluence of trends will only worsen without significant procedural changes and implementation of new guidance to OUD treatment.
SAMHSA’s previous guidance was restrictive, such that they served as a de facto rule on how OTPs practiced medicine; this was never the intent. Now that the restrictions are removed, the new path forward needs sensible discernment. Multidisciplinary treatment teams led by Medical Directors must agree on how to steer the ship and clearly articulate the safeguards necessary to ensure these regulatory changes achieve their intended impact.
The Transformative Power of MOUD
Multifaceted Approaches to Enhancing Outcomes
The efficacy of OTPs can be maximized by extending beyond medication provision. Successful outcomes hinge on multifaceted approaches that include increased access to treatment, improved linkages to ongoing care, and robust retention strategies.7
Research highlights the importance of integrating education and harm reduction efforts to reduce overdose fatality rates. Expanding evidence-based interventions, particularly those that directly mitigate overdose risks such as naloxone distribution and basic overdose prevention courses, could substantially reduce deaths in the short term.7 Statistics show that effective OUD treatment can positively impact individuals and communities.
The Promise of Expanding Treatment Access
Beyond expanding OUD treatment scope, there is a potential for broadening OUD access also. Evidence-based modelling studies highlight that interventions which directly reduce overdose risks—particularly through harm reduction efforts—can significantly decrease fatalities in the short term.7 Additionally, interventions aimed at improving Medication for opiate use disorder (“MOUD”) initiation and patient retention rates can improve the prevalence of MOUD and OUD treatment by 137% and 23% respectively, while reducing overdose rates by 10%.7
In rural regions and treatment deserts, broadening access to MOUD has yielded positive outcomes. A large-scale pilot study in Colorado reported significant reductions in the use of substances such as heroin, opioids, and alcohol. Patients also reported significant improvements in overall health metrics and reductions in pain, anxiety, and depression, further highlighting the comprehensive benefits of making OTPs more accessible.8
Addressing Treatment Retention Challenges
Treatment retention remains a critical challenge. Data from systematic reviews has found that often less than half of the patients in OTPs are retained at follow-up.9
Enhanced access to MOUD is a pivotal way of addressing this: studies indicate that patients who receive methadone or buprenorphine have higher retention rates compared to those who receive no medication.9 Specifically, methadone has shown superior retention rates compared to buprenorphine particularly in critical periods such as the end of pregnancy.10-12
Adopting a patient-centered approach that recognizes harm reduction and patient retention would allow a move towards effective, compassionate OUD treatment that meets the needs of the affected. The new regulatory rule changes allow us to explore these possibilities more freely. However, we must frame the conversation around the wise use of these newfound freedoms.
Dilemmas in Opioid Treatment Flexibility
The transition from stringent regulation offers both opportunities and challenges. With the regulatory brakes now released, it is imperative for medical directors to judiciously apply long term day-to-day controls, to ensure a safe transition. This places greater responsibility on providers to exercise professional judgment and establish safeguards that maintain treatment integrity and patient safety.
Certain changes, including the adoption of telehealth technology and updated terminology, have been broadly welcomed and supported as they expand access to care and reduce stigmatization.13
However, other aspects of the new regulations, such as the policies regarding methadone take-home flexibilities, have elicited a mixed reaction. Critics argue that without careful patient selection and added expectations, the new policies could inadvertently facilitate methadone abuse, blunting treatment progress at best and potentially contributing to the crisis at worse. There is apprehension that savvy individuals with bad intent may exploit take home flexibilities, leading to abuse of the healthcare system. In regards to increase diversion of MOUDs rebuttalist (?) correctly argue that diversion reflects unmet community needs that should be addressed rather than criminalized. 13 Albeit true, how OTPs should meet this need remains a challenge. Though there is evidence to support take-home doses as a safe option, some healthcare providers remain unconvinced, without further clarity.14-16
Initial take-home flexibility was widely used during the COVID-19 pandemic, doctors reasoned that the benefit outweighed the potential stated risk, but doctors have since scaled back flexibility initiatives, with many reversing their earlier orders. This conservative stance reflects the ongoing concerns among some medical professionals about the potential for misuse and the challenges of effectively managing these risks.
Moving forward, SAMHSA is to be commended for recognizing the importance of practitioner discretion in assessing risk factors and preventing diversion—tasks that are not new but will require renewed focus under the relaxed regulations.13 However, paving a unified path into the future remains crucial.
Maintaining Rigor in a More Flexible Framework
The need for careful implementation of take-home doses and methadone flexibility is clear. While providing flexibility, practitioners must protect both their patients and themselves. Overly liberal application of these guidelines could lead to adverse outcomes for patients and legal repercussions for medical professionals.
Therefore, providers should establish gateway industry standards related to take-home dose-methadone flexibilities—while still preserving the capacity for individualized care.
New Guardrails: Crafting Standards for Safer Opioid Treatment
As we adapt to the new regulations on methadone take-home doses, it is critical to establish medically prudent commonsense standards that ensure these changes are implemented safely and effectively. Here are four essential benchmarks that together form a comprehensive approach to increased patient autonomy in OUD treatment.
1. Evaluating Barriers to In-Person Program Attendance
To qualify for take-home doses, patients should meet specific thresholds preventing regular in-person treatment attendance. These barriers include logistical challenges like lengthy travel distances to treatment centers or medical conditions that make commuting difficult. Barriers may also include broader social and financial constraints. Patients may be saddled with caregiver responsibilities for a younger child or older adult. Patient’s employment responsibilities may conflict with attending a Medication Assisted Treatment (MAT), six times a week.
Meeting a barrier threshold is the first layer to be considered for take-home flexibility treatment, a position that’s currently supported by SAMHSA. However, while acknowledging and recognizing the limitations that barriers pose, it’s secondary to the safe handling, storage, and usage of MOUDs (especially methadone), which are paramount for patient safety and public health.
2. Establishing a Commitment Threshold for Take-Home Enrollment
To be considered for take-home doses, patients should also demonstrate commitment to their rehabilitation process. This may be evidenced by a mere willingness to seek MOUD. Patients may report a change in use pattern, that suggests a sporadic rather than chronic opioid exposure, suggesting a more controlled engagement with opioids rather than deep-seeded desire for euphoric thrills. A report on family and friend support can also illustrate a stable foundation for responsibility and accountability. Documented treatment history in OTPs may further validate an individual’s commitment to manage their treatment with a degree of self-reflection.
Patients should also have plans for the safe transport and storage of medications, which includes the use of lockboxes. These measures ensure not only the safety of the patient but also mitigate broader risks to public health by preventing diversion and misuse.
3. Establishing Opiate Overdose Competency (OOC)
A multiple-step OOC can play a critical role in arming patients and interested parties with the requisite knowledge necessary to navigate the challenging landscape of opiate abuse and overdose. Under the previous guidelines a patient would have to be free of illicit opiate for 90 days before that patient was considered an acceptable risk to receive one additional take home bottle. Is it inconceivable in the face of continued use opiate use that some expectation of overdose competency be desired if not demanded.
Building a Foundation with the Basic Overdose Prevention (BOP) Card
Overdose competency could begin with the Basic Overdose Prevention (BOP) certificate. This initiative, led by organizations like the American Academy of Addiction and Overdose Prevention (AAAOP), equips individuals with essential knowledge on drug-drug interactions that increase overdose risk, current drug use practices (such as scarfing and others) that lends to overdose possibilities, it also provides updates on potent emerging illicit opiates and sedatives entering the black market. The BOP certificate ensures that recipients have a comprehensive understanding of the factors that would lead to an opiate overdose.
While providers can’t dedicate several hours to training each client, this would provide a vitally important stopgap that meets the needs of providers and patients alike. Several other organizations such as the United States Taskforce on Overdose Prevention (USTOP) and the American Institute for Substance Use Credentialing (AISUC), are in process of receiving authorization to provide the BOP card.
4. Emergency Preparedness
Advancing to Opioid Overdose Prevention Programs (OOPP)
In addition to obtaining the BOP certification, patients should receive a naloxone kit for emergency preparedness. Most Opioid Treatment Programs OTPs are also Opioid Overdose Prevention Programs (OOPP) and routinely provide naloxone kits. These programs go deeper into the practical aspects of overdose response, including the use of naloxone. It compliments information learned from the BOP course.
Narcan training should be expected for all patients receiving take-home methadone flexibility doses. Each OTP has designated staff members who specialize in overdose response training. In a 15-minute in-service session with these trained professionals, patients would receive comprehensive training on the proper use of Narcan kits. The training includes hands-on demonstrations to ensure patients are confident and competent in administering the medication. Patients would share this knowledge with family members and cohorts of friends.
In cases where other preventive measures have failed, counseling and BOP training are complemented by naloxone training as the last line of defense against a fatal overdose. This final step boosts individual readiness and strengthens the community, encouraging patients to be active participants in maintaining safety in their environment.
Reinforcement through Provider-Led Training
To ensure that training is not only received but also applied, provider-led reinforcement is crucial. Providers should still assess their patients’ understanding of overdose competency, discuss local drug trends, and answer unresolved questions. This visit allows providers to review and reinforce overdose prevention strategies with patients, ensuring information is understood and can be used in real life. This visit should be documented for future reference. These steps are vital for maintaining a high standard of care, readiness and response within communities highly affected by OUD.
OOC is an ongoing process that involves continuing education and regular competency assessments. These assessments will be crucial for keeping the training relevant and up to date, ensuring that all individuals receiving methadone flexibility are more prepared to handle opioid sensitive encounters.
By establishing these four safeguards, we ensure that the new flexibility in methadone take-home regulations enhances patient care without compromising safety. These measures—preparedness – foster responsible autonomy in opioid treatment and set the stage for modern treatment.
A Call for Collaborative Action
We also aim to examine the updates within the context of your experiences, you, (the physicians, patients, counsellors, administrators and multidisciplinary teams) to whom these changes are directly relevant. Most importantly we call for meaningful discussion and encourage you to share insights and participate in shaping future opioid treatment. Your first-hand experiences are crucial for adapting to and maximizing the benefits of these regulatory changes.
Ongoing dialogue among all stakeholders—healthcare providers, patients, policymakers, and community leaders – is essential. A collaborative approach in continuously refining the application of these new freedoms will ensure they serve the best interests of patients while safeguarding the community.
Feedback from a wide range of stakeholders can provide diverse perspectives that may highlight unforeseen issues or areas for improvement. By encouraging open communication, we can gather data and insights that lead to more effective and compassionate care.
As part of our discussion, we’ve introduced possible industry standards that might support the responsible implementation of harm reduction interventions. It is important to reflect on these suggestions and consider their feasibility and impact. Are these measures practical? Do they address the core needs of those they’re meant to help? What adjustments or additions might make them more effective?
We invite you to join the dialogue—share your experiences, propose ideas, and raise questions. Whether here on community forums, or direct consultations, your input is invaluable in shaping a treatment that truly meets patients where they are.
References
1. Dydyk AM, Jain NK, Gupta M. Opioid Use Disorder. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Nitesh Jain declares no relevant financial relationships with ineligible companies. Disclosure: Mohit Gupta declares no relevant financial relationships with ineligible companies.: StatPearls Publishing
Copyright © 2024, StatPearls Publishing LLC.; 2024.
2. Keyes KM, Rutherford C, Hamilton A, Barocas JA, Gelberg KH, Mueller PP, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3.
3. Hedegaard H, Miniño AM, Spencer MR, Warner M. Drug overdose deaths in the United States, 1999–2020.
4. SAHMSA. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health. 2021.
5. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622.
6. Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9-17.
7. Nataraj N, Rikard SM, Zhang K, Jiang X, Guy GP, Jr., Rice K, et al. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder. JAMA Netw Open. 2024;7(4):e244617.
8. Amura CR, Sorrell TR, Weber M, Alvarez A, Beste N, Hollins U, et al. Outcomes from the medication assisted treatment pilot program for adults with opioid use disorders in rural Colorado. Substance Abuse Treatment, Prevention, and Policy. 2022;17(1):1.
9. Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22-35.
10. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128(1-2):71-6.
11. Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr. 2014;66(3):288-93.
12. Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013;74(4):605-13.
13. SAHMSA. Medications for the Treatment of Opioid Use Disorder. In: Services DoHaH, editor.: Office of the Federal Register, National Archives and Records Administration; 2024.
14. Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. The American Journal of Drug and Alcohol Abuse. 2021;47(6):722-9.
15. Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Subst Abuse Treat. 2021;131:108449.
16. Krawczyk N, Rivera BD, Levin E, Dooling BCE. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy. Lancet Public Health. 2023;8(3):e238-e46.
